Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
about
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerDifferentially expressed and activated proteins associated with non small cell lung cancer tissuesNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibElevated RABEX-5 expression predicts poor prognosis in non-small-cell lung cancer.Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells.Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on AfatinibThe treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.Tumor molecular profiling of NSCLC patients using next generation sequencing.Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.Proscillaridin A Promotes Oxidative Stress and ER Stress, Inhibits STAT3 Activation, and Induces Apoptosis in A549 Lung Adenocarcinoma Cells.Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
P2860
Q26771116-96436D7F-B5F3-42C9-AC61-513F7907C52AQ35805319-CBF73B46-F5ED-40E4-BF86-2FC304AF192EQ35807946-9C66C390-4CAF-4380-B375-E66FD4EA7E64Q36250677-5DC6668D-35F5-42CE-B1BD-544EDFCEE306Q37223268-293181D0-E2A8-4ED3-B8C2-AF69AF47F59AQ37636606-58AF4DA1-C142-4B2C-AB8A-34A7566DE3FBQ39339545-CA37F918-23E5-4253-9018-81CD9FC53E3CQ43128868-4E4C4480-FE2E-4EE3-B5D1-CAFF57670FCCQ47710730-5297D2B4-1BF1-4218-86B7-257719702F12Q49300205-7B479251-82CA-4FF2-B30F-95C1637C6F10Q52655141-C6AB59BE-B971-460C-BFD8-236A42B461E1Q52724253-4B0D15FE-35E7-4E3C-910C-3F6EE791868FQ55224621-BB9B8C25-4D00-4ECA-B1FB-C6DD7C04AE91Q55429658-E2CDF614-9690-47AA-9362-BC5713DCE44F
P2860
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@ast
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@en
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@nl
type
label
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@ast
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@en
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@nl
prefLabel
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@ast
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@en
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@nl
P2860
P3181
P356
P1476
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
@en
P2093
Natasha Leighl
P2860
P3181
P356
10.3389/FONC.2014.00329
P407
P577
2014-01-01T00:00:00Z